Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
Praxis Precision Medicines Inc. (NASDAQ:PRAX) on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures.
Open original source